Celgene touts mid-stage psoriasis results

Researchers for Celgene are changing the dosing and duration of their tests of an experimental psoriasis drug after seeing a significant reduction in severity and symptoms in a mid-stage study. A 260-patient study of CC-10004 demonstrated that 24.4 percent of patients treated with 20 milligrams of CC-10004 every 12 hours had a 75 percent or greater reduction in psoriasis severity and symptoms. A placebo registered a 10.3 percent reduction. Patients can now get doses of 30 mgs for up to six months and Celgene will expand the trial to include related conditions. No serious side effects were reported.

- see this release
- check out the AFX report

Related Articles:
Celgene goes global with $2.9B Pharmion buyout. Report
Array partners with Celgene, nets $40M upfront. Report
Celgene accelerates program on positive psoriasis data. Report
Insurers shun new biologics for psoriasis. Report